Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.530
+0.046 (9.49%)
At close: Mar 9, 2026, 4:00 PM EDT
0.525
-0.005 (-0.87%)
After-hours: Mar 9, 2026, 7:24 PM EDT
Longeveron Employees
Longeveron had 25 employees as of December 31, 2024. The number of employees increased by 1 or 4.17% compared to the previous year.
Employees
25
Change (1Y)
1
Growth (1Y)
4.17%
Revenue / Employee
$57,480
Profits / Employee
-$853,640
Market Cap
11.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| Imunon | 25 |
| BiomX | 20 |
| Moleculin Biotech | 17 |
| Soligenix | 16 |
| CalciMedica | 15 |
| BioVie | 13 |
| Cellectar Biosciences | 11 |
LGVN News
- 12 days ago - Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - GlobeNewsWire
- 24 days ago - Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - GlobeNewsWire
- 4 weeks ago - Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - GlobeNewsWire
- 5 weeks ago - Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - GlobeNewsWire
- 2 months ago - Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - GlobeNewsWire
- 3 months ago - Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - GlobeNewsWire
- 3 months ago - Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 3 months ago - Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire